Literature DB >> 18499325

Roles of reactive oxygen species and MAP kinases in the primary rat hepatocytes death induced by toosendanin.

Yunhai Zhang1, Xinming Qi, Likun Gong, Yan Li, Linlin Liu, Xiang Xue, Ying Xiao, Xiongfei Wu, Jin Ren.   

Abstract

Toosendanin (Tsn), a triterpenoid extracted from Melia toosendan Sieb et Zucc, possesses different pharmacological effects in human and important values in agriculture. However, liver injury has been reported when toosendanin or Melia-family plants, which contain toosendanin are applied. The mechanism by which toosendanin induces liver injury remains largely unknown. Here we reported that toosendanin induced primary rat hepatocytes death by mitochondrial dysfunction and caspase activation. Toosendanin led to decrease of mitochondrial membrane potential, fall in intracellular ATP level, release of cytochrome c to cytoplasm, activation of caspase-8, 9, and 3 and ultimately cell death. Level of reactive oxygen species (ROS) was also increased in hepatocytes after incubation with toosendanin. Catalase, the H2O2-decomposing enzyme, can prevent the reduction in ATP level and protect hepatocytes from toosendanin-induced death. The ERK1/2 (p44/42 MAP kinases) and JNK (c-Jun N-terminal kinase) were activated, but p38 MAPK was not activated by toosendanin. Inhibition of ERK1/2 activation sensitized hepatocytes to death and increased activity of caspase-9 and 3 in response to toosendanin. Inhibition of JNK attenuated toosendanin-induced cell death. These results suggested that toosendanin causes death of primary rat hepatocytes by mitochondrial dysfunction and caspase activation. Generation of ROS and MAP kinases activation might be involved in this process.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18499325     DOI: 10.1016/j.tox.2008.04.005

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  7 in total

1.  Inhibitory effect of a triterpenoid compound, with or without alpha interferon, on hepatitis C virus infection.

Authors:  Takako Watanabe; Naoya Sakamoto; Mina Nakagawa; Sei Kakinuma; Yasuhiro Itsui; Yuki Nishimura-Sakurai; Mayumi Ueyama; Yusuke Funaoka; Akiko Kitazume; Sayuri Nitta; Kei Kiyohashi; Miyako Murakawa; Seishin Azuma; Kiichiro Tsuchiya; Shinya Oooka; Mamoru Watanabe
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

2.  Anticancer effects of crude extract from Melia toosendan Sieb. et Zucc on hepatocellular carcinoma in vitro and in vivo.

Authors:  Xiao-Ling Liu; Hong Wang; Ling Zhang; You-Liang Wang; Jin Wang; Peng Wang; Xiao He; Yu-Juan He
Journal:  Chin J Integr Med       Date:  2015-09-17       Impact factor: 1.978

Review 3.  Reactive oxygen species: a double-edged sword in oncogenesis.

Authors:  Jin-Shui Pan; Mei-Zhu Hong; Jian-Lin Ren
Journal:  World J Gastroenterol       Date:  2009-04-14       Impact factor: 5.742

4.  A Chinese Herbal Decoction, Modified Yi Guan Jian, Induces Apoptosis in Hepatic Stellate Cells through an ROS-Mediated Mitochondrial/Caspase Pathway.

Authors:  Hung-Jen Lin; Ching-Ping Tseng; Chia-Fan Lin; Mei-Huei Liao; Chuan-Mu Chen; Shung-Te Kao; Ju-Chien Cheng
Journal:  Evid Based Complement Alternat Med       Date:  2010-09-26       Impact factor: 2.629

5.  Integrated analysis of microRNA and mRNA expression profiles highlights the complex and dynamic behavior of toosendanin-induced liver injury in mice.

Authors:  Xiaoyan Lu; Cai Ji; Wei Tong; Xueping Lian; Ying Wu; Xiaohui Fan; Yue Gao
Journal:  Sci Rep       Date:  2016-10-05       Impact factor: 4.379

Review 6.  Limonoids From the Genus Melia (Meliaceae): Phytochemistry, Synthesis, Bioactivities, Pharmacokinetics, and Toxicology.

Authors:  Wenxiang Fan; Linhong Fan; Zhengtao Wang; Li Yang
Journal:  Front Pharmacol       Date:  2022-01-24       Impact factor: 5.810

7.  Integrated expression profiles of mRNA and microRNA in the liver of Fructus Meliae Toosendan water extract injured mice.

Authors:  Jie Zheng; Cai Ji; Xiaoyan Lu; Wei Tong; Xiaohui Fan; Yue Gao
Journal:  Front Pharmacol       Date:  2015-10-19       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.